Did the Phase 3 pivotal studies for roflumilast specifically evaluate itch reduction?
Featuring Andrew Alexis, MD, MPH | Vice-Chair for Diversity and Inclusion, Dept. of DermatologyProfessor of Clinical Dermatology Weill Cornell MedicineNew York, NY | Published September 29, 2022
Related Media
Powered by Polaris TM